Tryptophan for Impaired AhR Signaling in Celiac Disease

🩺 Protocol Summary

This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related symptoms despite taking a GFD for more than 1 year and who score \> 40 on the Celiac Symptom Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.

Primary Research Facility: McMaster University (Hamilton, Ontario)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Tryptophan Metabolism Alterations?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged between 18 Years and 75 Years?

🔍 Protocol Specified Age Range: 18 Years to 75 Years

Able to attend required clinic visits at McMaster University (Hamilton, Ontario)?

🔍 Logistical Requirement: Site at McMaster University

📍 Primary Site Map

Site: McMaster University — Hamilton, Ontario

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.